power to make<br> an impact</span>

power to make
an impact

Motivated by her own experience with glioblastoma (GBM), Jessica Morris created and launched a movement designed to help GBM patients better manage their disease and to expedite clinical trial research.

Learn More
building a global <br>oncology platform</span>

building a global
oncology platform

Read our 2017 Annual Report to learn more about our business, our patients, our colleagues and our mission.

Learn More
driven in <br>facing cancer</span>

driven in
facing cancer

After receiving a glioblastoma diagnosis, Nikki Woolfolk felt relieved to learn the cause of her symptoms and began to take action.

Learn More
working <br>through cancer</span>

working
through cancer

Greg Schmidt, who has glioblastoma, has worked for the same company for 38 years and loves his job. Focusing on work has helped him through his diagnosis, treatment and recovery.

Learn More

the story
of Novocure

In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

Learn More

we can leverage physics to fight cancer

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

OUR THERAPY

explore our clinical pipeline

Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.

OUR PIPELINE

we are dedicated to improving the lives of cancer patients

Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.

PATIENT-FORWARD